- 1 Full Title: Risk of Heart Failure among Individuals with Metabolic Syndrome Components
- 2 Corresponding Author:
- 3 Rajan Lamichhane, PhD
- 4 Assistant Professor
- 5 Department of Clinical and Translational Sciences (DCTS)
- 6 Joan C. Edwards School of Medicine
- 7 Marshall University1600 Medical Center Drive, Room 256
- 8 Huntington, WV 25701
- 9 🖾 304-691-8648
- 10 <u>lamichhaner@marshall.edu</u>

11 Co-authors:

12	1.	Vijay Bharti, MD Student
13		Joan C Edwards School of Medicine
14		Marshall University
15		<u>bharti2@marshall.edu</u>
16		
17	2.	Aarshi R Lamichhane
18		Hurricane High School
19		<u>rclam123@gmail.com</u>
20		
21	3.	Kamran Zaheer, DO
22		Assistant Professor, Internal Medicine
23		Joan C Edwards School of Medicine
24		Marshall University
25		zaheer@marshall.edu
26	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27 28	Short '	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27 28	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27 28 29	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27 28 29	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27 28 29	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27 28 29 30	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27 28 29 30	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27 28 29 30 31	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure
26 27 28 29 30 31	Short	Title: Metabolic Syndrome Components and Risk of Heart Failure

33 <u>Abstract</u>

34 Metabolic dysfunction of metabolic syndromes (MetS) has been widely reported to be a 35 significant risk factor for heart failure (HF). While this interaction is well studied, what 36 combinations of MetS factors pose the greatest risk for HF are not well defined. We hypothesize 37 that some components of MetS are of higher risk of HF compared to others. We explored the 38 relationship between the independent components of MetS and their combinatory effect on the 39 risk of HF. All metabolic syndrome components except hypertriglyceridemia were significant 40 individually (P-value<0.001), while hypertension (HTN) and diabetes or insulin resistance (IR) 41 had the higher risk of developing heart failure when taken collectively. The odds of heart failure 42 among the individuals who had HTN and IR was 7.7 times those who didn't have any MetS 43 components. We observed the additive effect of number of metabolic components on HF, for the 44 individuals who had only one MetS symptom, the odd of HF was 5.4 time compared to those 45 who didn't have any of MetS symptoms. Similarly, these odds of HF were 6.4 and 7.4 times for 46 those who had at least 2 or at least 3 symptoms respectively. Even though obesity is a significant 47 risk factor for cardiovascular diseases, we found the protective effect of obesity on heart failure, 48 which is an interesting result and needs further investigation.

49 Keywords: Retrospective case-control study, metabolic syndrome, heart failure, obesity,

50 hypertension, insulin resistance, risk analysis

51

53 <u>Non-standard Abbreviations and Acronyms</u>

- 54 CVD CardioVascular Disease
- 55 MI Myocardinal Infaction
- 56 MetS Metabolic Syndrome
- 57 IR- Insulin Resistance
- 58 HTN Hypertension
- 59 HG HypertriGlyceridemia
- 60 HDL Low High-Density Lipoprotein
- 61 HF Heart Failure
- 62 BMI Body Mass Index
- 63 IHD Family history of Ischemic Heart Disease
- 64 CAD History of Coronary Artery Disease
- 65 OR Odds Ratio
- 66 AR Attributable Risk
- 67 HFpEF Heart Failure with preserved Ejection Fraction
- 68 HFrEF Heart Failure with reduced Ejection Fraction
- 69 HbA1c Hemoglobin A1c

71 Introduction

Cardiovascular disease (CVD) is the leading cause of death in the United States ¹ and CVD is the
most common cause of myocardial infarction (MI). An MI occurs every 40 seconds; every year,
about 805,000 people in the United States have an MI ² accounting for 13.4% of all registered
deaths in 2018 ¹.

76 Metabolic Syndrome (MetS) is associated with numerous adverse health outcomes including

77 CVD ³⁻⁹. MetS is comprised of five components – insulin resistance (IR), hypertension (HTN),

78 hypertriglyceridemia (HG), low high-density lipoprotein cholesterol (HDL), and obesity ¹⁰.

79 Several research studies focused on the relationship between MetS and Heart Failure (HF)¹¹⁻¹³,

80 but limited work shows the association between MetS factors and HF. The components of MetS

81 have been linked to an increased risk for HF¹⁴⁻¹⁶; however, their interactions are not defined. It

82 is not common to find individuals with only a single component of MetS, rather, they present

83 together as a constellation often unique to the individual. It is therefore important to study the

84 simultaneous effect of these components on HF as they overlap among the same group of

85 people. Understanding the risk of HF among each of the MetS components could help direct

86 screening and treatment. In our study, we intend to identify the MetS components and their

87 respective combinations that create the highest risk of developing HF.

Our study is focused on the Appalachian population as this region has a disproportionately
higher incidence of HF compared to the rest of the United States ¹⁷. Also, Appalachia performs
worse than the nation in several health indicators. According to the Appalachian Regional

91 Commission report ^{18,19}, 7 out of the 10 leading causes of death in the United States, including
92 CVD, are higher in the Appalachian Region compared to the nation.

93 This study of the rural Appalachian population is important to understand the mechanism of 94 HF among this medically underserved population. The presence of comorbidities, like smoking 95 and obesity, significantly affects the long-term morbidity and mortality of patients with HF ²⁰. 96 Population studies have shown that metabolic syndrome increases the risk of developing HF 97 and this effect is mediated by insulin resistance. However, obesity is a key component in 98 metabolic syndrome and a customary partner of insulin resistance because it is protective in 99 patients with established HF, although insulin resistance confers an increased risk of dying 100 from HF. Obesity, a key element of MetS, is often present alongside insulin resistance. In 101 patients with HF, obesity can offer a degree of protection, although insulin resistance is 102 associated with an increased risk of mortality from HF. This phenomenon is called the "obesity 103 paradox" accounting for the complexity of the relationship between HF and MetS²¹. This 104 paradoxical relationship between MetS and HF should further be investigated to understand 105 the relationship between MetS and HF. Our study aims to investigate this complex relationship 106 between MetS and HF, further breaking down into different individual components of MetS. It 107 is important to understand the role of each of the MetS components to develop customized 108 strategies for HF prevention and treatment. We explore the relationship between MetS and its 109 components with HF to determine which individuals will have a greater need for preventive or 110 therapeutic measures aimed at reducing the risk of HF. Recommendations from this study 111 could help in developing strategies and guidelines based on MetS components to alleviate the 112 burden of HF.

113 <u>Study Design and Methods</u>

114 Data sources and study design

115	This study included patients ages 18 and older who received service from the Marshall Health
116	Network between January 2017 and September 2023. The study population was primarily
117	located in Central and North Central Appalachia which includes the western part of West
118	Virginia, the Southern part of Ohio, and the eastern part of Kentucky. Patients were classified as
119	with or without metabolic syndrome if they met at least 3 of the following 5 conditions:
120	• Insulin Resistance (IR): Average Fasting glucose ≥100 mg/dL, HbA1c >= 5.7 at any point
121	or receiving drug therapy for hyperglycemia, or type 2 diabetes listed as a billing diagnosis or
122	under the patient's problem list.
123	• Hypertension (HTN): Blood pressure ≥130/85 mm Hg, receiving drug therapy for
124	hypertension, or hypertension listed as a billing diagnosis or under their problem list.
125	• Hypertriglyceridemia (HG): Average Triglycerides ≥150 mg/dL, receiving drug therapy
126	for hypertriglyceridemia, or hypertriglyceridemia listed as a billing diagnosis or under their
127	problem list.
128	• Low High-Density Lipoprotein Cholesterol (HDL): Average HDL-C < 40 mg/dL in men
129	or < 50 mg/dL in women, receiving drug therapy for reduced HDL-C or low HDL-C listed as a
130	billing diagnosis, or under their problem list.
131	• Obesity: Average BMI > 30, obesity listed as a billing diagnosis, or under their problem
132	list.

133	This retrospective case-control study has 121 HF cases. The equivalent control subjects were								
134	identified by matching age, gender, and heart disease history in the ratio of 1:3 using the nearest								
135	neighbor propensity score matching method. The patient data relevant to the study was								
136	6 extracted from Marshall Health Network's Data Warehouse. The study variables are listed								
137	below:								
138	1.	Demographic variables – Current Age and Gender							
139	2.	Body Mass Index (BMI)							
140	3.	Family history of ischemic heart disease (IHD) – patients with a family history of							
141		ischemic heart disease and other circulatory diseases.							
142	4.	History of MI							
143	5.	Social History (Tobacco and Alcohol use) – The use of any kind of tobacco, including							
144		smoking, or alcohol during the study period.							
145	6.	Inherited syndromes – whether the patient had a history of sickle cell disease, Graves'							
146		disease, or sleep apnea.							
147	7.	History of Coronary Artery Disease (CAD)							
148	8.	Presence or absence of Insulin Resistance, Hypertension, Low HDL,							
149		Hypertriglyceridemia, and Obesity							
150	9.	The number of MetS criteria met by the patient							
151	10.	Metabolic Syndrome (MetS) – Patients who met 3 or more of the 5 conditions mentioned							
152		above in variable 8 were classified as patients with MetS							

153 11. Status of HF

154 This study was approved by Marshall University IRB (FWA 00002704).

155 Statistical Approach

156 In this retrospective case-control study, we implemented the nearest neighbor propensity score

- 157 method to match the 121 HF cases with 363 control subjects that did not have HF. The cases
- 158 were matched by age, gender, and heart disease history.

159 The descriptive summaries were presented as mean ± SE for the continuous variables and 160 frequency (percent) ± SE for the categorical variables. The odds of HF among individuals who 161 met the criteria for MetS and other components were individually calculated. We investigated 162 how MetS components—IR, low HDL, HTN, and HG—individually and simultaneously 163 impacted the risk of HF by using logistic regression models after adjusting for other risk factors 164 (covariates) of HF. This ensures which components of MetS contributed to the higher risk of HF 165 when taken collectively. Once the important components were identified, we compared the risk 166 of HF among the individuals who had those components and their combinations against the 167 other components. In our analyses, HF status was the outcome variable, while MetS status – 168 comprising HTN, HG, HDL, and combinations of previously identified significant components, 169 each taken separately-served as the primary predictor variables. These results were further 170 validated by running logistic regressions of HF on the number of MetS components to assess for 171 an incremental increase in risk upon adding components. In the analyses, we controlled the 172 other variables: age, gender, history of tobacco and alcohol use, history of CAD, and inherited 173 syndromes.

All statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). Theresults were considered statistically significant when the p-values were less than 0.05.

176 <u>Results</u>

177	Table 1 presents the distribution of demographic and other controlled variables together with
178	individual MetS components of 484 individuals. In the study population, the median age was 56
179	years while the average BMI was 39.9 indicating an obese population, 72.3% of the population
180	was overweight or obese. There were more males (54.7%) than females (45.3%). 70.3% of
181	individuals were younger than 50, 19.4% were between 50 and 65, and 10.3% were older than
182	65. On average, 2.2 MetS criteria were met, and 44.2% of patients met MetS criteria. Most
183	patients showed obesity, HTN, and IR symptoms, and only 14.1% reported either low HDL or
184	high HG. 49.2% had some history of tobacco or alcohol use, 33.7% had previous MIs, 55.5% had
185	a family history of MI and 31.1% had inherited syndromes associated with HF. As the MetS
186	components occurred collectively, their individual existence was low (table 1). Due to the small
187	sample, we could not estimate the individual effect of these components alone on HF.

Table 1: Descriptive Summary								
Variables	Mean (SE)	Variables		Mean (SE)				
Total Sample	484	Total Sample		484				
	54.2(0.78)							
Age (in yrs.)	Median=56	Gender						
BMI	39.9(2.47)		Male	257(54.7%)				
No. of MetS Criteria	2.2(0.05)							
Met	Median=2		Female	213(45.3%)				
		Age Group						
	N (%)		< 50 yrs.	340(70.3%)				
HF			50-65 yrs	94(19.4%)				
Yes	121(25%)		>=65 yrs.	50(10.3%)				
No	363(75%)	Weight Category						

MetS				Obese	297(81.4%)
	Yes	214(44.2%)		Overweight	53(14.5%)
	No	270(55.8%)		Others	15(4.1%)
			Alcohol or		
No. of MetS			Tobacco use		
Components			(current or past)		
	0	32(6.6%)		Yes	238(49.2%)
	1	79(16.3%)		No	246(50.8%)
			Inherited		
	2	159(32.9%)	Syndromes		
	3	174(36%)		Yes	152(31.4%)
	4	38(7.9%)		No	332(68.6%)
	5	2(0.4%)	History of MI		
IR				Yes	163(33.7%)
	Yes	330(68.2%)		No	321(66.3%)
	No	154(31.8%)	Family History of	Heart MI	
HDL				Yes	268(55.4%)
	Yes	7(1.5%)		No	216(44.6%)
	No	477(98.6%)			
HTN	110	117 (201070)			
	Yes	386(79.8%)			
	No	98(20.3%)			
HG	110	20.070			
no	Ves	61(12.6%)			
	No	423(87.4%)			
IR Only	110	120(07.170)			
incomy	Ves	13(2.7%)			
	No	471(97.3%)			
	110	4/1(//.5/0)			
IIDL Only	Vos	0(0.0%)			
	No	484(100.0%)			
UTN Only	INU	404(100.078)			
IIIN Olly	Vac	20(6, 29/)			
	Ies No	30(0.270)			
	INO	434(93.876)			
ng Uniy	Vac	1(0.0%)			
	ies Na	1(0.0%)			
	INO	403(100.0%)			
Obese Only	N /				
	Yes	35(7.2%)			
	No	449(92.8%)			

SE- Standard

error

188

189	Table 2a presents the odds of HF among patients with different components of MetS except for
190	low HDL as there was not enough data to evaluate. MetS had a significantly higher risk of HF,
191	and MetS components IR and HTN also had a significantly higher risk of HF. Obesity had some
192	protective effect on HF while the effect of HG was not significant. In all estimations, the
193	covariates mentioned above were controlled to account for their effect on HF status. HF risk is
194	highest among patients with HTN, they had 6.2 times the odds of HF compared to no HTN.
195	Among all patients with HF and HTN, almost 80% were attributable to HTN. Similarly, the
196	odds of HF were 300% higher among patients with IR compared to the patients without, and
197	almost 70% of HF cases in this group were attributable to IR. The odds of HF are twice as high
198	in the MetS group compared to those without MetS. Additionally, the attributable risk of HF
199	due to MetS was 44.3%. Obesity appeared to have a protective effect on HF, the prevention

200 fraction of HF among these individuals was 62.4%.

Table 2a: Logistic regression analysis of Heart Failure on different Metabolic Syndrome components

		<u>Heart l</u>	Failure			
					AR% or	
				OR (95%	Prevention	P-
		Yes	No	CI)	Fraction	value
MetS						
	Yes	71(33.2%)	143(66.8%)	2(1.2, 3.1)	44.3	0.005
	No	50(18.5%)	220(81.5%)			
IR						
	Yes	106(32.1%)	224(67.9%)	4(2.2, 7.5)	69.8	< 0.001
	No	15(9.7%)	139(90.3%)			
HTN						
	Yes	115(29.8%)	271(70.2%)	6.2(2.4, 16.2)	79.5	< 0.001
	No	6(6.1%)	92(93.9%)			
HG						

	Yes	15(24.6%)	46(75.4%)	0.8(0.4, 1.5)	-	0.499
	No	106(25.1%)	317(74.9%)			
HDL**						
	Yes	3(42.9%)	4(57.1%)	NA	42.4	NA
	No	118(24.7%)	359(75.3%)			
Overweight/Ob	ese			0.2(0.1, 0.6)	62.4	0.004
	Yes	88(25.1%)	262(74.9%)			
	No	10(66.7%)	5(33.3%)			

NA- Not enough samples to evaluate

202	We estimated the effect of more than one component of MetS on HF in Table 2b. We observed
203	that HTN and IR together had a significant risk of HF, the odds of HF among those who had IR
204	and HTN was 7.7 times compared to those who didn't have any reported MetS components. In
205	all HF cases among the patients who had IR and HTN, almost 82% were attributable to IR and
206	HTN only. The addition of obesity and other factors in the combination of IR and HTN did not
207	increase the odds of HF at a significant rate. Among patients with obesity who also had IR and
208	HTN, the odds of HF were 7.9 times with 81.8% attributable risk compared to those who didn't
209	have any reported MetS. Due to the observed protective effect of both HG and obesity, the odds
210	of HF among individuals with these components were slightly less than 80%. Also, all other
211	combinations had insufficient data to evaluate the significance.

Table 2b: L	logistic	regression	analysis	of HF on	individual	MetS d	combinations
	0	0	7				

			AR% or		
				Prevention	P-
	Yes	No	OR	Fraction	value
IR and HTN only				81.5	
Yes	33(34%)	64(66%)	7.7(1.7,34.4)		0.002
None	2(6.3%)	30(93.8%)			
IR, HTN, and Obesity				81.8	

only

Yes	55(34.6%)	104 (65.4%)	7.9(1.8,34.4)		0.001
None	2(6.3%)	30 (93.8%)			
IR, HTN, HG, and Obesity only				78.0	
Yes	10(28.6%)	25(71.4%)	6(1.2,30)		0.017
None	2(6.3%)	30(93.8%)			

212

213 We justified the above findings by investigating the effect of metabolic syndrome components

on HF. Table 3 shows the additive effect of metabolic syndrome symptoms on HF.

					P-
	Yes	No	OR (95% CI)	AR%	value
At least one					
Yes	119(26.3%)	333(73.7%)	5.4(1.2, 22.8)	76.0	0.023
None	2(6.3%)	30(93.8%)			
At least two					
Yes	111(29.8%)	262(70.2%)	6.4(1.2, 27)	78.9	0.012
None	2(6.3%)	30(93.8%)			
At least three					
Yes	71(33.2%)	143(66.8%)	7.4(1.2, 32)	81.0	0.007
None	2(6.3%)	30(93.8%)			
At least four**					
Yes	12(30.0%)	28(70.0%)	6.4(1.2, 31.3)	79.0	0.021
None	2(6.3%)	30(93.8%)			

Table 3: Logistic regression of HF on total number of MetS components Heart Failure

** Not enough data to evaluate

215

The odds of HF had increased as the number of MetS components increased. The odds of HF with at least one MetS components was 5.4 times (*P* value=0.023) compared to individuals with no components. Similarly, individuals with at least 2 and at least 3 MetS components had odds of HF was 6.4 and 7.4 times, respectively, compared to those with no reported MetS. There were few individuals with at least 4 components; among these individuals, 79% of the risk of HF wassolely attributable to at least 4 MetS components.

222 Discussion

223 We explored the relationship between MetS and its components with HF which could provide 224 personalized HF screening, preventive, and treatment options for patients with HF. Overall, 225 insulin resistance and hypertension were the most important components of MetS that could 226 collectively increase the risk of HF. MetS and its components-IR, HTN, and obesity-were 227 significant risk factors for HF. Most patients had multiple components present, so the risk of 228 individual effects could be confounding. Instead, we collectively analyzed the components: the 229 patients with IR and HTN had a higher risk compared to those with at least one other 230 component – HG, obesity, or HTN. There is an increased risk of developing HF as the number 231 of metabolic components increases.

232 Our findings were in line with past research studies while also generating some novel results. 233 Several studies established the relationship between MetS and HF and indicated the increased 234 HF risk among patients with MetS²²⁻²³. Our results also identified MetS as an important risk 235 factor for HF. We identified HTN as the most significant contributing factor to HF risk, which 236 can be correlated to a physiologic basis as follows. Hypertension increases left ventricular 237 afterload and peripheral vascular resistance, leading to pressure and volume-mediated left 238 ventricle remodeling²⁴. This remodeling results in diastolic dysfunction, which is often the first 239 sign of increased load. Chronic hypertension, involving both pressure and volume overloads, 240 can lead to either concentric or eccentric left ventricular hypertrophy, associated with heart

failure with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF),
respectively ²⁴.

243 Diabetes is another important risk factor for HF. IR, the primary endocrine dysfunction 244 of diabetes, disrupts glucose uptake and utilization by cardiomyocytes, leading to energy 245 deficits and impaired contractility²⁵. This metabolic inflexibility generates reactive oxygen 246 species and induces mitochondrial dysfunction ²⁶. The pathophysiology of diabetes-associated 247 HF involves several key mechanisms. Elevated hemoglobin A1c (HbA1c) levels are associated 248 with an increased risk of HF. Hyperglycemia leads to the formation of advanced glycation end-249 products and the modification of proteins by β -N-acetylglucosamine, which can negatively 250 impact cardiac function ²⁷. Systemic inflammation observed in patients with diabetes likely 251 contributes to cardiac complications. Autonomic dysfunction, disturbances in myocardial 252 metabolism, cardiac remodeling, and poor perfusion are additional mechanisms of diabetes-253 induced HF²⁸.

We were not able to isolate the effects of individual components due to the size limitations as
these conditions were rarely observed as a single factor in our study population. However, we
found that both HG and low HDL levels were independently associated with an increased risk
of HF. Atherogenic dyslipidemia induced by HG and low HDL promotes endothelial
dysfunction and atherosclerosis, compromising coronary blood flow and explaining our finding
pathologically ²⁹.

We observed a protective effect of obesity on HF. This may be due to our choice of measurementunit for obesity-BMI. Individuals with obesity often have preserved skeletal muscle mass and

262 may have a better prognosis secondary to increased stroke volume and thus cardiac output 263 compared with their counterparts who have reduced lean mass and lower stroke volume and 264 cardiac output. Lean mass may play a major role in outcome differences seen in the HF 265 population³⁰. 266 There are several strengths to our study. First, a few studies investigated the relationship 267 between some of the MetS components (IR, HTN) with HF but often did not adjust other risk 268 factors. For most of our analyses, we adjusted for age, sex, BMI, tobacco use, alcohol 269 consumption, family history of HF, and inherited syndromes shown to be related to HF. 270 Second, it is unlikely to observe just a single component of MetS; it is important to study the 271 simultaneous effect of these components on HF. We investigated the additive effects of 272 metabolic components on HF and compared the risks of HF between patients with MetS and its 273 components. Our study is the first to focus on studying the additive effect of individual 274 metabolic syndrome components. 275 Third, we performed the risk analysis based on the number of components (table 3) and found 276 the increased odds of HF as the number of components increased, which is a novel finding. 277 This study also has some limitations. First, the analysis was limited to mainly Central and North 278 Central Appalachia, which may affect the generalizability of the study findings. However, the 279 identified factors reflect the general pattern for the US population. Second, we could not include 280 race, diet, and lifestyle information in the analyses even though they are significant risk factors 281 for HF ^{31,32}. There was less racial diversity in the data due to the demographic structure of this 282 region, with more than 90% of the population being White³³. Future research on HF should

- 283 consider adding these factors with other factors such as health beliefs, attitude toward HF
- screening and early detection, lifestyle, and SES as they relate to the disease etiology.
- 285 Furthermore, we could not perform subgroup analyses by age and gender due to data
- 286 limitations, so we controlled them in our analyses.
- 287 Metabolic syndrome, and its components, insulin resistance, hypertension, and obesity were
- 288 significant risk factors of HF. Multiple components are often present, and individuals with HTN
- and IR had a significantly higher risk of HF compared to individuals with no components or
- any other combinations of components. As the number of MetS components increases, and for
- 291 individuals with HTN and IR, treatment should be more aggressive for HF prevention
- 292 compared to those with fewer factors. This will improve the health of our population and
- 293 combat the marked increase in MetS and HF incidence nationally.

294 Acknowledgment

- 295 We acknowledge the Translational Sciences Core of COBRE/ACCORD, Clinical, and
- 296 Translational Sciences Department, Joan C Edwards School of Medicine, Marshall University for

analytics support.

298 <u>References</u>

- National Center for Health Statistics. Multiple Cause of Death 2018–2021 on CDC WONDER
 Database. Accessed February 2, 2024.
- Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics 2023 Update:
 A Report From the American Heart Association. *Circulation*. 2023;147:e93–e621.
- 303 3. Virani SS, Alonso A, Benjamin EJ, et al. On behalf of the American Heart Association
- 304 Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics
- 305 Subcommittee. Heart Disease and Stroke Statistics 2020 Update: A Report From the

306		American Heart Association. Circulation. 2012;141(9).
307		https://doi.org/10.1161/CIR.00000000000757.
308	4.	Esposito K, Chiodini P, Colao A, et al. Metabolic syndrome and risk of cancer: a systematic
309		review and meta-analysis. <i>Diabetes Care</i> . 2012; 35(11):2402–2411. doi: 10.2337/dc12-0336.
310	5.	Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with
311		the metabolic syndrome: a summary of the evidence. <i>Diabetes Care</i> , 2005: 28(7):1769–1778.
312		doi: 10.2337/diacare.28.7.1769.
313	6	Watanabe S. Yaginuma R. Ikejima K. et al. Liver diseases and metabolic syndrome. I
314	0.	Gastroenteroly 2008: 43, 509 https://doi.org/10.1007/s00535-008-2193-6
315	7	Raikou VD & Gavriil S Metabolic Syndrome and Chronic Renal Disease Diseases 2018 Jan
316	7.	24:6(1):12 doi: 10.3390/diseases6010012
317	8	Ritchie SA & Connell IMC The link between abdominal obesity metabolic syndrome and
318	0.	cardiovascular disease Nutrition Metabolism & Cardiovascular Diseases 2007:17 319e326
319	9	Shin IA Lee IH Lim SY et al. Metabolic syndrome as a predictor of type 2 diabetes and its
320	7.	clinical interpretations and usefulness. <i>I Diabetes Investig</i> 2013 Jul 8:4(4):334-43. doi:
321		10 1111/idi 12075
327	10	National Institute of Health What is Metabolic Syndrome? Accessed February 10, 2024
323	11	Burger P M Koudstaal S Dorresteijn I A N et al Metabolic syndrome and risk of
324	11	incident heart failure in non-diabetic nations with established cardiovascular disease
325		International Journal of Cardiology 2023:379 66–75 https://doi.org/10.1016/j.jicard.2023.03.024
326	12	Crundy S M Obesity Metabolic Syndrome and Cardiovascular Disease The Journal of
327	12	Clinical Endocrinology & Matabolics 2004:89(6), 2595–2600, https://doi.org/10.1210/ic.2004
328		0372
320	13	Porrona Filardi P. Paolillo S. Costanzo P. Savarosa C. Trimarco B. Bonow R. The role of
330	10	motabolic syndromo in boart failuro. Euronean Heart Journal, 2015:36(39), 2630–2634
331		https://doi.org/10.1093/ourboarti/oby350
332	1/	Purwowiyoto S. L. & Prowara A. S. Motabolic syndrome and heart failure: Mechanism and
333	14	management Medicine and Pharmacy Reports 2021:94(1) 15-21 https://doi.org/10.15386/mpr
334		1884
335	15	<u>1004</u> Ebong IA Coff DC Ir Rodriguez CI Chen H Bertoni AC Mechanisms of heart failure in
338	15	obosity. Obes Res Clin Pract 2014 Nov Doc:8(6):0540 8. doi: 10.1016/j.orgp.2013.12.005
337	16	Vang CD, Pan WO, Fong S, et al. Insulin Resistance Is Associated With Heart Englure With
338	10	Parage CD, 1 and WQ, Feng S, et al. Insulin Resistance is Associated with Heart Assoc. 2022 Oct
330		4:11(10):0026184 doi: 10.1161/JAHA 122.026184
240	17	4,11(19).e020104. doi: 10.1101/JAHA.122.020104
240	17.	10, 2024
341 242	10	19, 2024.
342 312	10	Amorica Accessed February 19, 2024
343 211	10	America. Accessed redruary 17, 2024.
344 245	19.	and Princh Spots, Hoolth Core Systems, Accessed Echrysons 24, 2024
345		and bright Spots- health Care Systems. Accessed February 24, 2024.

- 346 20. Cardarelli K, Westneat S, Dunfee M, May B, Schoenberg N, Browning S. Persistent disparities in smoking among rural Appalachians: Evidence from the Mountain Air Project. 347 348 BMC Public Health. 2021;21(1), 270. https://doi.org/10.1186/s12889-021-10334-6 349 21. Herath J, & Brown, C. (2013). An Analysis of Adult Obesity and Hypertension in 350 Appalachia. Global Journal of Health Science. 2013;5(3), 127–138. 351 https://doi.org/10.5539/gjhs.v5n3p127.
- 352 22. Gargiulo P, Marsico F, Renga F, et al. The metabolic syndrome in heart failure: insights to 353 specific mechanisms. Heart Fail Rev. 2020 Jan;25(1):1-7. doi: 10.1007/s10741-019-09838-6.
- 354 23. Arcopinto M, Schiavo A, Salzano A, et al. Metabolic Syndrome in Heart Failure: Friend or 355 Foe? Heart Fail Clin. 2019 Jul;15(3):349-358. doi: 10.1016/j.hfc.2019.02.004.
- 356 24. Du Cailar G, Pasquie JL, Ribstein J, Mimran A. Left ventricular adaptation to hypertension 357 and plasma renin activity. J Hum Hypertens. 2000;14:181–188. doi: 10.1038/sj.jhh.1000974.
- 358 25. Lopez B, Gonzalez A, Querejeta R, Larman M, Diez J. Alterations in the pattern of collagen 359 deposition may contribute to the deterioration of systolic function in hypertensive patients 360 with heart failure. J Am Coll Cardiol. 2006;48:89–96. doi: 10.1016/j.jacc.2006.01.077.
- 361 26. Liu M, Lv J, Pan Z, Wang D, Zhao L, Guo X. Mitochondrial dysfunction in heart failure and 362 its therapeutic implications. Frontiers in Cardiovascular Medicine. 2022;9, 945142. 363 https://doi.org/10.3389/fcvm.2022.945142
- 364 27. Prakoso D, De Blasio MJ, Qin C, et al. Phosphoinositide 3-kinase (p110 alpha) gene delivery 365 limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model 366 with established diastolic dysfunction. Clin Sci (Lond). 2017; 131: 1345.
- 367 28. Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: mechanisms 368 and new treatment strategies targeting antioxidant signaling pathways. *Pharmacol Ther.* 369 2014; 142: 375.
- 370 29. Grundy, SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin 371 resistance. Clinical Cornerstone. 2006;8 Suppl 1, S21-27. https://doi.org/10.1016/s1098-372 3597(06)80005-0
- 373 30. Di Carli MF, Bianco-Batlles D, Landa ME, et al. Effects of autonomic neuropathy on 374 coronary blood flow in patients with diabetes mellitus. Circulation. 1999; 100: 813.
- 375 31. Billingsley HE, Hummel SL, Carbone S. The role of diet and nutrition in heart failure: A 376 state-of-the-art narrative review. Prog Cardiovasc Dis. 2020 Sep-Oct;63(5):538-551. doi: 377 10.1016/j.pcad.2020.08.004.
- 378 32. Larsson SC, Tektonidis TG, Gigante B, Akesson A, Wolk A. Healthy Lifestyle and Risk of 379 Heart Failure. Circulation. 2016; 9 (4). 380

https://doi.org/10.1161/CIRCHEARTFAILURE.115.002855.

- 381 33. Pollard K, Jacobsen LA. The Appalachian region: A data overview from the 2008–2012 382 American community survey chartbook. PRB. 2014.
- 383
- 384
- 385